Prostaid

Prostaid Biologics is a biotechnology company specializing in the development of targeted therapies and diagnostic tools for prostate cancer. The company's core technology revolves around the discovery of novel biomarkers and the engineering of monoclonal antibodies with high specificity for malignant prostate tissue. Their lead research programs include the development of antibody-drug conjugates (ADCs) and radio-immunotherapeutics designed to treat advanced and metastatic prostate cancer. By integrating diagnostic imaging with therapeutic intervention, Prostaid Biologics seeks to advance the field of theranostics and provide personalized care for cancer patients.